Galectin Therapeutics (GALT) Research & Development (2010 - 2026)

Galectin Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Research & Development fell 65.6% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $10.0 million (down 71.33% YoY), while the FY2025 annual figure was $14.3 million, down 60.93% from the prior year.
• Research & Development was $2.2 million for Q1 2026 at Galectin Therapeutics, up from $1.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $11.1 million in Q4 2024 to a low of $1.9 million in Q4 2025.
• Historically, Research & Development has averaged $6.9 million across 5 years, with a median of $7.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 64.48% in 2022, then sank 82.6% in 2025.
• A 5-year view of Research & Development shows it stood at $9.0 million in 2022, then dropped by 8.65% to $8.2 million in 2023, then jumped by 35.01% to $11.1 million in 2024, then tumbled by 82.6% to $1.9 million in 2025, then advanced by 15.42% to $2.2 million in 2026.
• The last three Research & Development figures came in at $2.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.